From: Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
Cell line | NRAS mutation | Other known mutations |
---|---|---|
M202 | NRASQ61L | EGFR amplification |
CDKN2A homozygous deletion | ||
M207 | NRASQ61L | MITF amplification |
EGFR L747_P753 > S | ||
PTEN heterozygous deletion | ||
M243 | NRASQ61H homozygous | PTENE156G heterozygous |
CTNNB1_D32Y | ||
M244 | NRASQ61K heterozygous | |
M245 | NRASQ61K heterozygous | TP53R273H |
M249AR4 | NRASQ61K heterozygous | MITF amplification |
BRAFV600E heterozygous | PTEN homozygous deletion | |
AKT2 amplification | ||
M296 | NRASQ61R heterozygous | |
M311 | NRASQ61L homozygous | |
M318 | NRASQ61L heterozygous | PIK3CAC420R |
M376 | NRASQ61K heterozygous | |
BRAFV600E heterozygous | ||
M408 | NRASQ61K heterozygous | |
SBCL2 | NRASQ61K homozygous | |
SKMEL173 | NRASQ61K | CTNNB1 D32G |
CCND1 amplification | ||
WM1366 | NRASQ61L heterozygous |